INCY — INCYTE CORP
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 879169 ·
Last close
$119.52
Market Cap
$24.23B
52W High
$132.60
52W Low
$92.18
ADV30
2,044,391
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 1,272,676,000 | 1,168,176,000 | 324,173,000 | 303,330,000 | 7,339,113,000 | 3,461,114,000 | 1,716,266,000 |
| Dec 2025 | 1,506,835,000 | 1,385,735,000 | 383,963,000 | 299,279,000 | 6,957,973,000 | 3,097,817,000 | 1,790,495,000 |
| Sep 2025 | 1,365,980,000 | 1,266,980,000 | 431,296,000 | 424,169,000 | 6,330,356,000 | 2,455,006,000 | 1,679,162,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,516,782,000
Investing CF
$-191,910,000
Financing CF
$198,537,000
CapEx
$-95,898,000
Dividends Paid
—
Buybacks
$-103,000
EPS Diluted TTM
$7.08
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$517,099,000
Inventory
$115,624,000
Receivables
$1,051,499,000
ST Investments
$554,711,000
EBIT TTM
$1,776,198,000
Pretax Income TTM
$1,773,861,000
Interest Exp TTM
$2,337,000
Analysts
22
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,819,530,240
EBITDA
$1,942,312,960
Free Cash Flow
$1,180,664,576
Enterprise Value
$20,432,322,560
Total Cash
$4,535,739,904
Total Debt
$38,267,000
Shares Out
202,697,746
Trailing EPS
$7.85
Book Value
$26.04
ROE
30.7%
ROA
16.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 5,141,242,000 | 1,342,790,000 | 1,286,650,000 | 6,957,973,000 | 1,790,495,000 | — | 1,413,498,000 |
| Dec 2024 | 4,241,217,000 | 101,294,000 | 32,615,000 | 5,444,322,000 | 1,996,694,000 | — | 335,337,000 |
| Dec 2023 | 3,695,649,000 | 655,358,000 | 597,599,000 | 6,782,107,000 | 1,592,270,000 | — | 496,487,000 |
| Dec 2022 | 3,394,635,000 | 591,626,000 | 340,660,000 | 5,840,984,000 | 1,470,865,000 | — | 969,941,000 |
TTM Snapshot
Revenues TTM
$3,693,186,000
NetIncome TTM
$572,239,000
OpCashFlow TTM
$0
Assets (Latest)
$5,444,322,000
Forward EPS
$8.77
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MEDP | Medpace Holdings, Inc. | $16.11B | $577.11 | — |
| IQV | IQVIA HOLDINGS INC. | $38.68B | $235.02 | — |
| IDXX | IDEXX LABORATORIES INC /DE | $44.10B | $559.07 | — |
| ICLR | ICON PLC | $12.62B | $163.57 | — |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $11.20B | $232.51 | — |
News headlines (Yahoo Finance, 1h cache)
Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod
2026-07-29 17:22 · Yahoo
Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
2026-07-29 10:00 · Yahoo
Incyte Corp (INCY) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic ...
2026-07-28 19:01 · Yahoo
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
2026-07-28 16:40 · Yahoo
Incyte Q2 Earnings Call Highlights
2026-07-28 14:04 · Yahoo
Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics
2026-07-28 13:30 · Yahoo
Incyte Tops Second-Quarter Expectations but Shares Slip on Lower Revenue Outlook
2026-07-28 13:29 · Yahoo
Incyte (INCY) Q2 Earnings and Revenues Top Estimates
2026-07-28 12:15 · Yahoo
Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q2 CY2026 But Full-Year Sales Guidance Misses Expectations Significantly
2026-07-28 11:37 · Yahoo
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-07-28 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.